Rigaku and SPERA PHARMA Initiate Strategic Partnership to Advanced Pharmaceutical Development
Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc. (headquarters: Osaka; President & Representative Director: Keitaro Iwaki; hereinafter “SPERA PHARMA”) have initiated a strategic partnership aimed at accelerating and transforming pharmaceutical development by leveraging the two companies’ cutting-edge technologies and extensive expertise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417047994/en/
Left: Keitaro Iwaki, President & Representative Director, SPERA PHARMA; Right: Jun Kawakami, President & CEO, Rigaku
SPERA PHARMA will use XtaLAB Synergy-ED, an integrated platform for electronic diffraction provided by Rigaku, for contract analytical services, thereby offering customers robust support in pharmaceutical development.
The XtaLAB Synergy-ED incorporates 3D ED/MicroED1, which is utilized for the structure analysis of substances, including microscopic crystals and minute quantities of crystalline powder. This sophisticated technology provides sufficiently high resolution to determine atomic-level structures, enabling the detailed elucidation of molecular structures of organic compounds and similar substances.
SPERA PHARMA is currently the world’s only company in the pharmaceutical industry offering contract analytical services with the XtaLAB Synergy-ED. Rigaku will extend technical support to SPERA PHARMA for its contract analytical operations.
Furthermore, the two companies are collaborating closely to advance research utilizing the XtaLAB Synergy-ED and to actively share information on the application methods and analytical technologies.
Through this partnership, Rigaku and SPERA PHARMA aim to provide robust support at the forefront of pharmaceutical development, playing pivotal roles in pioneering the future of medicine.
1: Stands for “Three-Dimensional Electron Diffraction/Microcrystal Electron Diffraction.” A method for analysis of crystalline structures using electronic diffraction.
Example of Joint Research and Use
“Detection of Hydrogen Atoms Using Only 3D ED/MicroED and Contribution to Structure Determining Salts or Cocrystals,” Crystal Growth ＆ Design, 2025, 25, 1, 129–135
URL: https://pubs.acs.org/doi/10.1021/acs.cgd.4c01421
(Registration required to read.)
About the Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku-holdings.com/english
About SPERA PHARMA
SPERA PHARMA was established in July 2017 in the Juso area of Yodogawa-ku, Osaka. It is a contract development and manufacturing organization (CDMO) specializing in Chemistry, Manufacturing and Controls (CMC) pharmaceutical sciences, including process chemistry, formulation development, and analytical development, as well as the manufacturing of investigational drugs. The company’s expert research team, which has extensive experience and proven results, works flexibly in all phases of pharmaceutical development from the early stage to final drug application. SPERA PHARMA is a one-stop provider of comprehensive services and solutions to meet customer needs. For further information, please visit spera-pharma.co.jp/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20250417047994/en/
Contacts
Press Contact:
Sawa Himeno
Head of Communications Dept., Rigaku Holdings Corporation
prad@rigaku.co.jp
+81 90 6331 9843
Ayako Tsuboi
Marketing Communications, Sales Dept., SPERA PHARMA, Inc.
mkouhou@spera-pharma.co.jp
+81 6-7653-6818
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Streamlines Network and Security Operations by Utilizing Keysight’s Application Fusion Platform18.11.2025 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, and Keysight Technologies, Inc. (NYSE: KEYS) today announced that Armis’ cyber exposure management technology will now run directly on the Keysight Vision E1S network packet brokers, with additional models expected to support Application Fusion in the future. Through the Application Fusion interface, Armis’ technology can now run directly on the Keysight network packet brokers, combining network visibility with continuous cyber exposure management and security capabilities. By providing immediate, actionable insights across the entire network, without the need for additional hardware, security teams can respond to threats faster, proactively reduce risk and increase operational efficiency. “Businesses must see and secure every asset in their environment to effectively protect against today’s evolving threats,” said Nadir Izrael, CTO and Co-Founder at Armis. “Using both network visibility and security with cyber exposure managemen
Parse Biosciences Announces FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis18.11.2025 15:00:00 EET | Press release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a breakthrough technology that unlocks the full potential of formalin-fixed, paraffin-embedded (FFPE) samples. By enabling whole transcriptome capture from archived tissues at single cell resolution, this innovation opens new possibilities for discovery in oncology, translational research, and precision medicine. The use of FFPE samples for single cell RNA sequencing (scRNA-seq) has traditionally been limited to profiling a predefined list of genes due to RNA degradation and fragmentation, reducing transcriptome coverage and discovery potential. Parse’s breakthrough overcomes these challenges with a novel split-pool combinatorial barcoding method that enables true transcriptome-wide scRNA-seq of FFPE-preserved tissues through its unique RNA capture chemistry. This advancement allows researchers to analyze thousands to millions of cells from hundreds of samples simultaneo
KP Labs and Frontgrade Gaisler Join Forces to Advance Fault-Tolerant Computing for Next-Generation Space Missions18.11.2025 15:00:00 EET | Press release
KP Labs, a European Leader in delivering autonomous systems for space applications and Frontgrade™ Gaisler Technologies, a leading provider of high-reliability electronic solutions for space and national security missions have signed a Memorandum of Understanding during the Space Tech Expo Europe in Bremen, Germany. The agreement establishes a framework for collaboration in developing and validating advanced on-board computing architectures designed to increase the autonomy and resilience of future space missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118359687/en/ As satellite operators and mission designers increasingly rely on on-board data processing and autonomy, maintaining fault tolerance and reliability has become a critical priority. To meet these demands, modern spacecraft integrates radiation-hardened components and advanced FDIR (Fault Detection, Isolation and Recovery) systems that ensure stable oper
ACE Fiber uses Adtran’s Mosaic One Clarity AI solution for proactive assurance, faster resolution and fewer truck rolls18.11.2025 15:00:00 EET | Press release
Adtran today announced that ACE Fiber, the broadband subsidiary of Mississippi’s ACE Power, is using its Mosaic One Clarity solution, built on the REAL AI platform, to move from reactive troubleshooting to proactive assurance across ACE Fiber’s expanding network. Mosaic One Clarity consolidates network and in-home data, identifies likely root causes and provides guided actions that help teams resolve issues faster and avoid unnecessary site visits. By detecting early signs of fiber performance issues and showing which subscribers are affected, Mosaic One Clarity enables more right-first-time resolutions. Early results show up to 75% fewer trouble tickets in the first month, reducing operational strain and improving customer satisfaction. “Our goal was simple – stop reacting and start preventing,” said Sean M. McGrath, GM and CEO of ACE Fiber. “With Adtran’s Mosaic One Clarity, we can anticipate issues and resolve them before they disrupt service. That shift means fewer on-site visits,
Sharjah Emerges as a Global Hub for Medical Innovation and Collaborative R&D18.11.2025 14:55:00 EET | Press release
In the United Arab Emirates, where cities like Abu Dhabi and Dubai consistently rank among the world's most forward-thinking, the Emirate of Sharjah, the country's cultural and knowledge capital, has decisively positioned itself as a premier hub for research and innovations in healthcare. This transformation is primarily driven by the Sharjah Research, Technology and Innovation Park (SPARK) formerly SRTIP, SRTI Park. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118121763/en/ SPARK Headquarters (SPARK HQ) (Photo: AETOSWire) This ambition was powerfully demonstrated during the recent "Sharjah Next: Healthcare" forum, which transcended a typical conference, evolving into a powerful statement of intent. It assembled a host of global healthcare luminaries, including Professor Sir Magdi Yacoub, a pioneer in cardiothoracic surgery; Professor Humaid Obaid Al-Shamsi, a leading Emirati oncologist; and Dr. Vladimir Ivkovic of Harv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom